Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.
Procopio G, Chiuri VE, Giordano M, Alitto AR, Maisano R, Bordonaro R, Cinieri S, Rossetti S, De Placido S, Airoldi M, Galli L, Gasparro D, Ludovico GM, Guglielmini PF, Carella C, Nova P, Aglietta M, Schips L, Beccaglia P, Sciarra A, Livi L, Santini D; ABItude Study Group. Procopio G, et al. Among authors: carella c. ESMO Open. 2022 Apr;7(2):100431. doi: 10.1016/j.esmoop.2022.100431. Epub 2022 Apr 8. ESMO Open. 2022. PMID: 35405438 Free PMC article.
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Cecere SC, Giannone G, Salutari V, Arenare L, Lorusso D, Ronzino G, Lauria R, Cormio G, Carella C, Scollo P, Ghizzoni V, Raspagliesi F, Di Napoli M, Mazzoni E, Marchetti C, Bergamini A, Orditura M, Valabrega G, Scambia G, Maltese G, De Matteis E, Cardalesi C, Loizzi V, Boccia S, Naglieri E, Scandurra G, Pignata S. Cecere SC, et al. Among authors: carella c. Gynecol Oncol. 2020 Jan;156(1):38-44. doi: 10.1016/j.ygyno.2019.10.023. Epub 2019 Nov 4. Gynecol Oncol. 2020. PMID: 31699415 Free article.
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
Cecere SC, Musacchio L, Bartoletti M, Salutari V, Arenare L, Lorusso D, Ronzino G, Lauria R, Cormio G, Naglieri E, Scollo P, Marchetti C, Raspagliesi F, Greggi S, Cinieri S, Bergamini A, Orditura M, Valabrega G, Scambia G, Martinelli F, De Matteis E, Cardalesi C, Loizzi V, Perniola G, Carella C, Scandurra G, Giannone G, Pignata S. Cecere SC, et al. Among authors: carella c. Int J Gynecol Cancer. 2021 Jul;31(7):1031-1036. doi: 10.1136/ijgc-2020-002343. Epub 2021 May 14. Int J Gynecol Cancer. 2021. PMID: 33990353
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Roviello G, Gambale E, Giorgione R, Santini D, Stellato M, Fornarini G, Rebuzzi SE, Basso U, Bimbatti D, Doni L, Nesi G, Bersanelli M, Buti S, De Giorgi U, Galli L, Sbrana A, Conca R, Carella C, Naglieri E, Pignata S, Procopio G, Antonuzzo L. Roviello G, et al. Among authors: carella c. Cancer Med. 2022 Aug;11(16):3084-3092. doi: 10.1002/cam4.4681. Epub 2022 Mar 20. Cancer Med. 2022. PMID: 35312175 Free PMC article.
Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study.
Basso U, Paolieri F, Rizzo M, De Giorgi U, Bracarda S, Antonuzzo L, Atzori F, Cartenì G, Procopio G, Fratino L, D'Arcangelo M, Fornarini G, Zucali P, Cusmai A, Santoni M, Pipitone S, Carella C, Panni S, Deppieri FM, Zagonel V, Tortora G. Basso U, et al. Among authors: carella c. Cancers (Basel). 2022 May 4;14(9):2293. doi: 10.3390/cancers14092293. Cancers (Basel). 2022. PMID: 35565422 Free PMC article.
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin.
Iacovelli R, Ciccarese C, Brunelli M, Battelli N, Buttigliero C, Caserta C, Buti S, Santini D, Carella C, Galli L, Verri E, Ermacora P, Merler S, Masini C, De Vivo R, Milesi L, Spina F, Rizzo M, Sperduti I, Fornarini G, Tortora G. Iacovelli R, et al. Among authors: carella c. Ann Oncol. 2022 Nov;33(11):1179-1185. doi: 10.1016/j.annonc.2022.07.011. Epub 2022 Aug 2. Ann Oncol. 2022. PMID: 35926813 Free article. Clinical Trial.
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis.
Rebuzzi SE, Signori A, Stellato M, Santini D, Maruzzo M, De Giorgi U, Pedrazzoli P, Galli L, Zucali PA, Fantinel E, Carella C, Procopio G, Milella M, Boccardo F, Fratino L, Sabbatini R, Ricotta R, Panni S, Massari F, Sorarù M, Santoni M, Cortellini A, Prati V, Soto Parra HJ, Atzori F, Di Napoli M, Caffo O, Messina M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Roviello G, Llaja Obispo MA, Porta C, Buti S, Fornarini G, Banna GL. Rebuzzi SE, et al. Among authors: carella c. Front Oncol. 2022 Sep 23;12:955501. doi: 10.3389/fonc.2022.955501. eCollection 2022. Front Oncol. 2022. PMID: 36212433 Free PMC article.
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.
Vignani F, Tambaro R, De Giorgi U, Giannatempo P, Bimbatti D, Carella C, Stellato M, Atzori F, Aieta M, Masini C, Hamzaj A, Ermacora P, Veccia A, Scandurra G, Gamba T, Ignazzi G, Pignata S, Di Napoli M, Lolli C, Procopio G, Pierantoni F, Zonno A, Santini D, Di Maio M; Meet-URO12 Investigators. Vignani F, et al. Among authors: carella c. Eur Urol. 2023 Jan;83(1):82-89. doi: 10.1016/j.eururo.2022.09.025. Epub 2022 Oct 8. Eur Urol. 2023. PMID: 36216658 Clinical Trial.
156 results